Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pitavastatin - Kowa

Drug Profile

Pitavastatin - Kowa

Alternative Names: Alipza; Itavastatin; Livalo; Livazo; Nisvastatin; NK 104; NK-104-CR; NK-104-LH; NK-104-PH; NKS 104; P 872441; Pitavastatin Calcium; Redevant; Trolise; Vezepra

Latest Information Update: 21 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nissan Chemical Industries
  • Developer AbbVie; Algorithm; Daiichi Sankyo Company; Eli Lilly and Company; ESTEVE; JW Pharmaceutical; Kowa; Mitsubishi Tanabe Pharma Corporation; Nissan Chemical Industries; Recordati
  • Class Antihyperlipidaemics; Carboxylic acids; Cyclopropanes; Fluorobenzenes; Quinolines; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia
  • Registered Hyperlipoproteinaemia type IIa
  • Discontinued Alzheimer's disease

Most Recent Events

  • 19 Jun 2019 Registered for Hypercholesterolaemia (In children, In adolescents) in USA (PO)
  • 15 Jan 2019 The US District Court, Southern District of New York, upholds patent (patent numbers 8 557 993) protection for pitavastatin
  • 02 Aug 2018 Merck completes a phase I pharmacokinetic trial in patients with renal insufficiency in USA (PO) (NCT03311841)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top